Aortic, Atherosclerosis and Stenosis

Disease drivers in aortic stenosis vs atherosclerosis

JAMA Cardiology

NOVEMBER 5, 2024

Aortic stenosis (AS) due to fibrosis and calcification of the aortic valve is a hazardous component of cardiovascular disease burden—after developing symptomatic AS, patients survive for an average of less than 2 years without treatment.

Atherosclerosis

Atherosclerosis Aortic Stenosis Aortic valve

Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome

Frontiers in Cardiovascular Medicine

APRIL 24, 2024

Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic premature aging disease that is historically fatal in teenage years, secondary to severe accelerated atherosclerosis. With this longer lifespan, calcific aortic stenosis (AS) was identified as an emerging critical risk factor for cardiac death in older patients.

Stenosis

Stenosis Aortic Peripheral Arterial Disease TAVR

Aortic valve perivascular adipose tissue computed tomography attenuation in patients with aortic stenosis

Heart BMJ

APRIL 15, 2024

Objective Aortic stenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aortic valve. HU, p=0.099).

Aortic valve

Aortic valve Aortic Stenosis Atherosclerosis

Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis

Open Heart

MARCH 24, 2023

Our perspectives on aortic stenosis (AS) are changing. The pathophysiology of calcific AS (CAS) is complex, yet can be characterised similarly to that of atherosclerosis. In addition, their integration with cardiovascular MRI can provide accurate risk stratification, aiding aortic valve replacement decision making.

Stenosis

Stenosis Aortic Aortic valve Biomarkers

Cholesterol Crystal Dissolution Rate of Serum Predicts Outcomes in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. Journal of the American Heart Association, Ahead of Print. In multivariate analysis, low CCDR (hazard ratio, 2.21 [95% CI, 0.99–4.92],P=0.04)

Aortic valve

Aortic valve Cholesterol Aortic Stenosis

Long?Term Outcomes After Transcatheter Aortic Valve Implantation in Patients With Chronic Inflammatory Disease

Journal of the American Heart Association

FEBRUARY 23, 2024

BackgroundChronic inflammatory disease (CID) accelerates atherosclerosis and the development of aortic stenosis. Data on long‐term outcomes after transcatheter aortic valve implantation (TAVI) in those patients are missing.

Aortic valve

Aortic valve Aortic Outcomes Atrial Fibrillation

Brachiocephalic Artery Access for Transcatheter Aortic Valve Replacement

All About Cardiovascular System and Disorders

MAY 19, 2024

Transcatheter aortic valve replacement (TAVR) is increasing in popularity for symptomatic severe aortic stenosis. Transfemoral arterial route is the most commonly used approach for TAVR, also known as TAVI or transcatheter aortic valve implantation. No calcifications in the artery causing vascular stenosis.

Aortic valve

Aortic valve Aortic TAVR Open-Heart Surgery

An undergraduate who is an EKG tech sees something. The computer calls it completely normal. How about the physicians?

Dr. Smith's ECG Blog

MAY 20, 2024

The Queen of Hearts disagrees, diagnosing OMI with high confidence: Case Continued: The EKG was not immediately recognized by the emergency provider, who ordered a CT scan to rule out aortic dissection at 1419. There is an area of dense white in the middle of the circle consistent with atherosclerosis. The blue circle shows the LCx.

Chest Pain

Chest Pain Blood Pressure Ischemia STEMI

Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease

Circulation

NOVEMBER 8, 2023

BACKGROUND:High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide.

Aortic valve

Aortic valve Heart Disease Atherosclerosis Aortic

Lipoprotein(a) measurement – how, why and in whom?

The British Journal of Cardiology

AUGUST 1, 2024

Genome-wide association and Mendelian randomisation studies have identified lipoprotein(a) (Lp[a]) as an emerging risk factor for calcific aortic stenosis and a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) in different ethnicities. HEART UK recommends Lp(a) measurement in specific ‘at-risk’ cohorts.

Risk Factors

Risk Factors Atherosclerosis Laboratory Stenosis

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection.

CME

CME Obesity Heart Failure Biomarkers

Why You Need To Measure apoB To Assess Your Cardiovascular Risk

Dr. Paddy Barrett

NOVEMBER 7, 2023

The fundamental characteristic of atherosclerosis is when a cholesterol particle becomes trapped in the artery wall. It is the inflammatory response to this particle retention that causes the formation of atherosclerosis 1. Lipoprotein particles entering the subintimal space causing atherosclerosis. CE = Cholesterol Ester.

Cholesterol

Cholesterol Atherosclerosis Stenosis Aortic

Abstract 114: “Failing” DAPT? Think Again

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

However, CTA head and neck 4 days later demonstrated 90 percent stenosis of the mid left V2 at the C3‐4 level and a 75‐90 percent stenosis of the left mid V2 segment at the C5‐6 level (hard and soft plaque in these areas). He also had moderate stenosis of the right V4 segment.

Stenosis

Stenosis Peripheral Arterial Disease Atherosclerosis Pacemaker

Lipoprotein(a) in atherosclerotic heart disease and familial hypercholesterolaemia

The British Journal of Cardiology

AUGUST 1, 2024

Lipoprotein(a) (Lp[a]) can improve the accuracy of assessment of atherosclerotic cardiovascular disease and the risk of aortic valve stenosis. Currently, there is no specific treatment to lower its circulating concentration. Raised Lp(a) is a feature of familial hypercholesterolaemia.

Aortic valve

Aortic valve Heart Disease Blood Pressure Risk Factors

Cardiovascular Update

Disease drivers in aortic stenosis vs atherosclerosis

Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome

Aortic valve perivascular adipose tissue computed tomography attenuation in patients with aortic stenosis

Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis

Cholesterol Crystal Dissolution Rate of Serum Predicts Outcomes in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Long?Term Outcomes After Transcatheter Aortic Valve Implantation in Patients With Chronic Inflammatory Disease

Brachiocephalic Artery Access for Transcatheter Aortic Valve Replacement

An undergraduate who is an EKG tech sees something. The computer calls it completely normal. How about the physicians?

Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease

Lipoprotein(a) measurement – how, why and in whom?

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Why You Need To Measure apoB To Assess Your Cardiovascular Risk

Abstract 114: “Failing” DAPT? Think Again

Lipoprotein(a) in atherosclerotic heart disease and familial hypercholesterolaemia

Stay Connected